FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891466495> ?p ?o ?g. }

• W2891466495 endingPage "3324" @default.
• W2891466495 startingPage "3317" @default.
• W2891466495 abstract "Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases? Isis Gayed,1 Vivian Salama,2 Lydia Dawood,1 Steven Canfield,3 David Wan,1 Chunyan Cai,4 Usha Joseph,1 Robert Amato5 1Nuclear Medicine Section, Department of Diagnostic and Interventional Imaging, University of Texas Health Science Center at Houston, 2Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center, 3Division of Urology, Department of Surgery, 4Division of Clinical and Translational Science, Department of Internal Medicine, 5Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA Background: Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an addition to the host of available therapies in the USA as a treatment option for metastatic castrate-resistant prostate cancer (mCRPC) with bone metastases. This study describes our initial experience in patients treated with Ra-223 dichloride. It attempts to optimize patients’ selection for the best outcome from Ra-223 dichloride therapy.Methods: Consecutive patients who were referred for treatment with Ra-223 dichloride were prospectively followed. Patients’ demographics, functional status per the Eastern Cooperative Oncology Group (ECOG) performance score, pain level per the numeric rating score (NRS), prostate-specific antigen (PSA), creatinine, and hematological values were compared at baseline and at the end of therapy. Patients also had a bone scan before starting therapy and at the end of therapy. Patients were divided into the favorable response (FR) group if their pain and/or functional status improved and the unfavorable response (UR) group if they did not improve, deteriorated, or deceased. Bone scan findings before and after Ra-223 dichloride therapy were compared in both the FR and UR groups.Results: Twenty patients were treated with Ra-223 dichloride. Twelve patients had innumerable bone metastases, three patients had super scans, and three patients had two to seven bone lesions. Two patients were lost to follow-up after the first injection. There were eight patients in the FR group and 10 patients in the UR group. Patients with UR had mean ECOG and NRS pain scores of 1.3 and 5.0 versus 0.8 and 4.4 in the FR group. The mean PSA and creatinine levels in the UR group were 445.2 ng/mL and 1.2 mg/dL versus 22.7 ng/mL and 1.1 mg/dL in the FR group. The mean hemoglobin, platelets, and absolute neutrophil values were 11.2 g/dL, 314.9 K/cmm, and 7.3 K/cmm in the UR group versus 11.6 g/dL, 207.0 K/cmm, and 6.2 K/cmm in the FR group. Seven of the eight patients with FR had a bone scan at the end of therapy showing improvement in five patients, a mixed response in one patient, and progression in another patient. Five patients in the UR group completed five or six injections and had bone scans showing flare of bone metastases in three patients, progression in one patient, and improvement in the fifth patient. Three patients in the UR group died after the first or second injections. Two of these patients had baseline super scans and the third one had widespread bone metastases.Conclusion: mCRPC patients with lower PSA levels at baseline and fewer bone lesions are more likely to respond favorably to Ra-223 dichloride therapy. Keywords: Radium-223 dichloride, castrate-resistant bone metastases, prostate cancer, radioactive therapy" @default.
• W2891466495 created "2018-09-27" @default.
• W2891466495 creator A5002664801 @default.
• W2891466495 creator A5006532012 @default.
• W2891466495 creator A5014373184 @default.
• W2891466495 creator A5037439192 @default.
• W2891466495 creator A5049780941 @default.
• W2891466495 creator A5062834106 @default.
• W2891466495 creator A5064334845 @default.
• W2891466495 creator A5064764696 @default.
• W2891466495 date "2018-09-01" @default.
• W2891466495 modified "2023-09-29" @default.
• W2891466495 title "Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?" @default.
• W2891466495 cites W1796050564 @default.
• W2891466495 cites W1913797671 @default.
• W2891466495 cites W1985734141 @default.
• W2891466495 cites W2005958584 @default.
• W2891466495 cites W2035877913 @default.
• W2891466495 cites W2037064486 @default.
• W2891466495 cites W2051267208 @default.
• W2891466495 cites W2064219355 @default.
• W2891466495 cites W2119991097 @default.
• W2891466495 cites W2141454098 @default.
• W2891466495 cites W2150865892 @default.
• W2891466495 cites W2170731023 @default.
• W2891466495 cites W2264243378 @default.
• W2891466495 cites W2342919577 @default.
• W2891466495 cites W2345212046 @default.
• W2891466495 cites W2412816437 @default.
• W2891466495 cites W2483834070 @default.
• W2891466495 cites W2487933695 @default.
• W2891466495 cites W2522755457 @default.
• W2891466495 cites W2529227491 @default.
• W2891466495 cites W2560832549 @default.
• W2891466495 cites W2574500438 @default.
• W2891466495 cites W2582011737 @default.
• W2891466495 cites W2588172683 @default.
• W2891466495 cites W2633412237 @default.
• W2891466495 cites W4205145397 @default.
• W2891466495 cites W72089627 @default.
• W2891466495 doi "https://doi.org/10.2147/cmar.s166218" @default.
• W2891466495 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6135075" @default.
• W2891466495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30233247" @default.
• W2891466495 hasPublicationYear "2018" @default.
• W2891466495 type Work @default.
• W2891466495 sameAs 2891466495 @default.
• W2891466495 citedByCount "3" @default.
• W2891466495 countsByYear W28914664952020 @default.
• W2891466495 countsByYear W28914664952022 @default.
• W2891466495 countsByYear W28914664952023 @default.
• W2891466495 crossrefType "journal-article" @default.
• W2891466495 hasAuthorship W2891466495A5002664801 @default.
• W2891466495 hasAuthorship W2891466495A5006532012 @default.
• W2891466495 hasAuthorship W2891466495A5014373184 @default.
• W2891466495 hasAuthorship W2891466495A5037439192 @default.
• W2891466495 hasAuthorship W2891466495A5049780941 @default.
• W2891466495 hasAuthorship W2891466495A5062834106 @default.
• W2891466495 hasAuthorship W2891466495A5064334845 @default.
• W2891466495 hasAuthorship W2891466495A5064764696 @default.
• W2891466495 hasBestOaLocation W28914664951 @default.
• W2891466495 hasConcept C121608353 @default.
• W2891466495 hasConcept C126322002 @default.
• W2891466495 hasConcept C143998085 @default.
• W2891466495 hasConcept C2777783956 @default.
• W2891466495 hasConcept C2780192828 @default.
• W2891466495 hasConcept C2780737065 @default.
• W2891466495 hasConcept C71924100 @default.
• W2891466495 hasConceptScore W2891466495C121608353 @default.
• W2891466495 hasConceptScore W2891466495C126322002 @default.
• W2891466495 hasConceptScore W2891466495C143998085 @default.
• W2891466495 hasConceptScore W2891466495C2777783956 @default.
• W2891466495 hasConceptScore W2891466495C2780192828 @default.
• W2891466495 hasConceptScore W2891466495C2780737065 @default.
• W2891466495 hasConceptScore W2891466495C71924100 @default.
• W2891466495 hasLocation W28914664951 @default.
• W2891466495 hasLocation W28914664952 @default.
• W2891466495 hasLocation W28914664953 @default.
• W2891466495 hasLocation W28914664954 @default.
• W2891466495 hasLocation W28914664955 @default.
• W2891466495 hasOpenAccess W2891466495 @default.
• W2891466495 hasPrimaryLocation W28914664951 @default.
• W2891466495 hasRelatedWork W122177069 @default.
• W2891466495 hasRelatedWork W194201398 @default.
• W2891466495 hasRelatedWork W1988873325 @default.
• W2891466495 hasRelatedWork W2158271544 @default.
• W2891466495 hasRelatedWork W2528118407 @default.
• W2891466495 hasRelatedWork W2895671943 @default.
• W2891466495 hasRelatedWork W2902305985 @default.
• W2891466495 hasRelatedWork W3023250508 @default.
• W2891466495 hasRelatedWork W3164067785 @default.
• W2891466495 hasRelatedWork W4383552306 @default.
• W2891466495 hasVolume "Volume 10" @default.
• W2891466495 isParatext "false" @default.
• W2891466495 isRetracted "false" @default.
• W2891466495 magId "2891466495" @default.
• W2891466495 workType "article" @default.